newsfilter
← Latest News
Business Wire·

Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

  • Innoviva, Inc. will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 10:00 a.m. E.T.
  • The virtual conference webcast will be accessible via the "Events & Presentations" section of Innoviva's investor relations website at https://investor.inva.com/presentations-events.
  • An archived replay of the fireside chat will be available on the company website after the event date.
  • Innoviva operates as a diversified holding company with a core royalties portfolio, the Innoviva Specialty Therapeutics platform, & strategic healthcare investments.
  • The company receives royalties from Glaxo Group Limited on sales of RELVAR®, BREO® ELLIPTA®, & ANORO® ELLIPTA®.
  • Innoviva's critical care & infectious disease assets include XACDURO® for hospital-acquired bacterial pneumonia, NUZOLVENCE® for gonorrhea, GIAPREZA® for shock, XERAVA® for intra-abdominal infections, & ZEVTERA® licensed from Basilea Pharmaceutica.
  • Contact for investor relations inquiries is Eleanor Barisser at Eleanor.barisser@inva.com.
  • Media & investor inquiries should be directed to Argot Partners at (212) 600-1902 or innoviva@argotpartners.com.